Home/Pipeline/FP-020 (BMS-986235)

FP-020 (BMS-986235)

Idiopathic Pulmonary Fibrosis (IPF)

Phase 2Active

Key Facts

Indication

Idiopathic Pulmonary Fibrosis (IPF)

Phase

Phase 2

Status

Active

Company

Foresee Pharmaceuticals

About Foresee Pharmaceuticals

Foresee Pharmaceuticals is a purpose-driven, clinical-stage biopharma focused on improving patient quality of life through innovative drug delivery and novel therapeutics. Its core strategy is built on two pillars: a proprietary Stabilized Injectable Formulation (SIF) platform for creating long-acting injectables that enhance compliance, and a pipeline of first/best-in-class New Chemical Entities (NCEs) for severe, underserved diseases. Key achievements include advancing multiple programs into late-stage clinical trials, such as FP-045 for Fanconi Anemia and its SIF-based Leuprolide for Central Precocious Puberty, while establishing a global partnership strategy to commercialize its products worldwide.

View full company profile

Therapeutic Areas

Endocrinology Rare Diseases Pulmonary Fibrosis Opioid Use Disorder

Other Idiopathic Pulmonary Fibrosis (IPF) Drugs

Drug	Company	Phase	Status
OATD-01	Molecure	Phase II	Active, recruiting
Buloxibutid (C21)	Vicore Pharma	Phase 2b	Active, Now Enrolling
AP02	Avalyn Pharmaceuticals	Phase 2	Active
Gento-Fibrose Pulmonaire Program	Genoscience Pharma	Preclinical	Active
SM001 (alidornase/Tigerase)	SarcoMed USA	Research	Active
NLM-001	Nelum Pharma	Phase 1	Active
GNS-3545 (ROCK2 Inhibitor)	Genosco	Phase 1	Active
TG2 Inhibitor Program	Isterian Biotech	Preclinical	Active
Taladegib (ENV-101)	Endeavor BioMedicines	Phase 2b	Active
CAL101	Calluna Pharma	Phase 2	Active
NVP-13	Velvio	Pre-clinical	Active
LASN01	Lassen Therapeutics	Preclinical	Active